William J. Muller
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Osteopontin (OPN), a key structural protein in the extracellular matrix, plays a pivotal role in regulating the local tumor microenvironment and systemic immunity during cancer progression. Recognizing that tumor cells do not exist in isolation but rather interact with a multitude of stromal components that significantly influence patient outcomes and therapy responses, this review focuses on the role of OPN in nontumor cells in the context of solid cancers and the associated phenotypic and mechanistic insights. We explore how OPN influences the behavior of various innate and adaptive immune cells, including NK cells, neutrophils, macrophages, dendritic cells, myeloid-derived suppressor cells, B cells, and T cells, as well as structural stromal cells such as fibroblasts, endothelial cells, and adipocytes. The review highlights the roles of OPN in modulating these stromal cells and their multiaxial influence on tumorigenesis and metastasis. These complex interplays offer insights into potential diagnostic and therapeutic strategies around OPN/stromal-mediated pathways in cancer progression and recurrence.
Year:
2025
Intracellular and extracellular OPN signaling on tumor stromal cells. Tumor cells and stromal cells can express and retain OPN intracellularly, which supports diverse cell type–specific functions such as promoting macrophage clonogenicity, supporting MDSC immunosuppressive phenotype, maintaining B-cell self-reactivity, sustaining endothelial cell wound healing capacity, and inducing a brown adipocyte phenotype. In parallel, tumor cells and stromal cells can secrete OPN into the TME. Cells expressing OPN receptors respond to extracellular OPN, most of which respond through activation, proliferation, migration, and secondary interactions with other stromal cells. Additionally, extracellular OPN can elicit cell type–specific functions, including NET formation, MDSC extramedullary myelopoiesis, and endothelial cell tubule formation. SASP, senescence-associated secretory phenotype. Created in BioRender. Muller, W. (2025) https://BioRender.com/cf6yfg1 .
Year:
2025
S1 - GSEA Hallmark Results, S2 - RPPA Quantification, S3 - IHC of pERBB2 antibody validation, S4 - NRG RNA levels in VCaP xenograft progression series, S5 - Western blot densitometry, S6 - IGV representation of ChIPseq data, S7 - IHC of clinical trial samples for pERBB2
Year:
2025
Purpose: ErbB2 activity is increased in a subset of prostate cancer, but the gene is rarely amplified. This study sought to identify mechanisms driving increased ErbB2 activity and their role in progression to castration-resistant prostate cancer (CRPC). Experimental Design: ErbB2 signaling was interrogated with a combination of immunohistochemistry, reverse-phase protein array, and RNA sequencing in cell lines, xenografts, and clinical tumors at various stages of castration resistance. Sensitivity to ErbB2 inhibitors was tested in vitro and in vivo . Results: ErbB2 activation, identified by IHC with an antibody against phosphorylated ErbB2, was present in ∼26% of residual tumors in radical prostatectomies after neoadjuvant androgen signaling inhibition (ASI) and in advanced CRPC. The ErbB3/ErbB2-activating ligand NRG1 was found by IHC in ∼75% of neoadjuvant-treated tumors. NRG1 mRNA was rapidly increased by ASI in prostate cancer cells and xenografts and was increased in post-ASI data sets. Overexpression of an active ERBB2 splice variant (d16ERBB2) was also increased rapidly after ASI in prostate cancer cells and was found in a subset of CRPC. ErbB2 signaling in all models remained sensitive to the covalent ErbB2 inhibitor neratinib, which enhanced responses to castration and suppressed the growth of castration-resistant xenografts with ErbB2 activation. Conclusions: Increased ErbB2 signaling is a rapid adaptation to ASI and contributes to castration resistance. Increases in NRG1 and d16ERBB2 contribute to increased ErbB2 signaling. Potent ErbB2 antagonists may enhance responses to ASI in castration-sensitive prostate cancer, and ErbB2 phosphorylation may be a biomarker for tumors that will respond in CRPC.
Year:
2025
Osteopontin (OPN), a key structural protein in the extracellular matrix, plays a pivotal role in regulating the local tumor microenvironment and systemic immunity during cancer progression. Recognizing that tumor cells do not exist in isolation but rather interact with a multitude of stromal components that significantly influence patient outcomes and therapy responses, this review focuses on the role of OPN in nontumor cells in the context of solid cancers and the associated phenotypic and mechanistic insights. We explore how OPN influences the behavior of various innate and adaptive immune cells, including NK cells, neutrophils, macrophages, dendritic cells, myeloid-derived suppressor cells, B cells, and T cells, as well as structural stromal cells such as fibroblasts, endothelial cells, and adipocytes. The review highlights the roles of OPN in modulating these stromal cells and their multiaxial influence on tumorigenesis and metastasis. These complex interplays offer insights into potential diagnostic and therapeutic strategies around OPN/stromal-mediated pathways in cancer progression and recurrence.
Year:
2025
The tumor–immune microenvironment (TIME) is a critical determinant of therapeutic response. However, the mechanisms regulating its modulation are not fully understood. HER2Δ16, an oncogenic splice variant of the HER2, has been implicated in breast cancer and other tumor types as a driver of tumorigenesis and metastasis. Nevertheless, the underlying mechanisms of HER2Δ16-mediated oncogenicity remain poorly understood. Here, we show that HER2∆16 expression is not exclusive to the clinically HER2 + subtype and associates with a poor clinical outcome in breast cancer. To understand how HER2 variants modulated the tumor microenvironment, we generated transgenic mouse models expressing either proto-oncogenic HER2 or HER2Δ16 in the mammary epithelium. We found that HER2∆16 tumors were immune cold, characterized by low immune infiltrate and an altered cytokine profile. Using an epithelial cell surface proteomic approach, we identified ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) as a functional regulator of the immune cold microenvironment. We generated a knock-in model of HER2Δ16 under the endogenous promoter to understand the role of Enpp1 in aggressive HER2 + breast cancer. Knockdown of Enpp1 in HER2Δ16-derived tumor cells resulted in decreased tumor growth, which correlated with increased T-cell infiltration. These findings suggest that HER2Δ16-dependent Enpp1 activation associates with aggressive HER2 + breast cancer through its immune modulatory function. Our study provides a better understanding of the mechanisms underlying HER2Δ16-mediated oncogenicity and highlights ENPP1 as a potential therapeutic target in aggressive HER2 + breast cancer.
Year:
2025
Recurrent breast cancers often develop resistance to standard-of-care therapies. Identifying targetable factors contributing to cancer recurrence remains the rate-limiting step in improving long-term outcomes. In this study, we identify tumor cell-derived osteopontin as an autocrine and paracrine driver of tumor recurrence. Osteopontin promotes tumor cell proliferation, recruits macrophages, and synergizes with IL-4 to further polarize them into a pro-tumorigenic state. Macrophage depletion and osteopontin inhibition decrease recurrent tumor growth. Furthermore, targeting osteopontin in primary tumor-bearing female mice prevents metastasis, permits T cell infiltration and activation, and improves anti-PD-1 immunotherapy response. Clinically, osteopontin expression is higher in recurrent metastatic tumors versus female patient-matched primary breast tumors. Osteopontin positively correlates with macrophage infiltration, increases with higher tumor grade, and its elevated pathway activity is associated with poor prognosis and long-term recurrence. Our findings suggest clinical implications and an alternative therapeutic strategy based on osteopontin’s multiaxial role in breast cancer progression and recurrence.
Year:
2024
The tumor immune microenvironment (TIME) is a critical determinant of therapeutic response. However, the mechanisms regulating its modulation are not fully understood. HER216, an oncogenic splice variant of the human epidermal growth factor receptor (HER2), has been implicated in breast cancer and other tumor types as a driver of tumorigenesis and metastasis. Nevertheless, the underlying mechanisms of HER2Δ16-mediated oncogenicity remain poorly understood. Here, we show that HER2∆16 expression is not exclusive to the clinically HER2+ subtype and associates with a poor clinical outcome in breast cancer. To understand how HER2 variants modulated the tumor microenvironment, we generated transgenic mouse models expressing either proto-oncogenic HER2 or HER2∆16 in the mammary epithelium. We found that HER2∆16 tumors were immune cold, characterized by low immune infiltrate and an altered cytokine profile. Using an epithelial cell surface proteomic approach, we identified ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) as a functional regulator of the immune cold microenvironment. We generated a knock-in model of HER2Δ16 under the endogenous promoter to understand the role of Enpp1 in aggressive HER2+ breast cancer. Knockdown of Enpp1 in HER2Δ16-derived tumor cells resulted in decreased tumor growth, which correlated with increased T-cell infiltration. These findings suggest that HER2Δ16-dependent Enpp1 activation associates with aggressive HER2+ breast cancer through its immune modulatory function. Our study provides a better understanding of the mechanisms underlying HER2Δ16-mediated oncogenicity and highlights ENPP1 as a potential therapeutic target in aggressive HER2+ breast cancer.
Year:
2024
Metabolic reprogramming, a hallmark of tumorigenesis, involves alterations in glucose and fatty acid metabolism. Here, we investigate the role of Carnitine palmitoyl transferase 1a (Cpt1a), a key enzyme in long-chain fatty acid (LCFA) oxidation, in ErbB2-driven breast cancers. In ErbB2+ breast cancer models, ablation of Cpt1a delays tumor onset, growth, and metastasis. However, Cpt1a-deficient cells exhibit increased glucose dependency that enables survival and eventual tumor progression. Consequently, these cells exhibit heightened oxidative stress and upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) activity. Inhibiting Nrf2 or silencing its expression reduces proliferation and glucose consumption in Cpt1a-deficient cells. Combining the ketogenic diet, composed of LCFAs, or an anti-ErbB2 monoclonal antibody (mAb) with Cpt1a deficiency significantly perturbs tumor growth, enhances apoptosis, and reduces lung metastasis. Using an immunocompetent model, we show that Cpt1a inhibition promotes an antitumor immune microenvironment, thereby enhancing the efficacy of anti-ErbB2 mAbs. Our findings underscore the importance of targeting fatty acid oxidation alongside HER2-targeted therapies to combat resistance in HER2+ breast cancer patients.
Year:
2024
Year:
2023
Collaborators (9)
Heikki Joensuu
University of Helsinki
Christopher Dennehy
Beth Israel Deaconess Medical Center
David Einstein
Beth Israel Deaconess Medical Center
Philippe Roux
Scientific Director
Université de Montréal
Morag Park
McGill University
Nancy Lin
Associate Professor of Medicine
Dana-Farber Cancer Institute
Mark Barok
University of Helsinki
Michel L. Tremblay
James McGill Distinguished Professor
McGill University
Steven Balk
Harvard University
Make your next move.
Prepare your application
Review drafts before you send them.